Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Cancer Immunol Immunother · 2024 · PMC11447177 · PMID 39358611

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendp = 0.052so close (0.05 < p ≤ 0.1)

Patients with molecular-informed second-line therapy showed a trend toward survival benefit (HR: 0.23; p = 0.052).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.